Assistant Professor, Medicine, University of California, San Francisco, School of Medicine

Hematology

Dr. Andrea L. Harzstark works in the field of Hematology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is a top medical college. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Dr. Andrea L. Harzstark is a published doctor and has 23 publications published. The lastest was: 'Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulatin...'

Publications

---

• Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate Cancer and the predictive value of circulatin...
• Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
• Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer.
• Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.
• A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic Renal cell carcinoma.
• Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate.
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate Cancer: results from an open-label, multicenter phase I/II study.
• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
• Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.
• Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary Renal cell carcinoma.
• Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate Cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defen...
• A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate Cancer.
• Novel therapeutic strategies in development for prostate Cancer.
• Immunotherapy for prostate Cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
• A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive Prostate ...
• A phase 1 study of everolimus and sorafenib for metastatic clear cell Renal cell carcinoma.
• Castrate-resistant prostate Cancer: therapeutic strategies.
• Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate Cancer previously treated with docetaxel-based the...
• Immunotherapeutics in development for prostate Cancer.
• Sipuleucel-T for the treatment of prostate Cancer.
• Therapies in development for castrate-resistant prostate Cancer.

Schools

---

• Stanford University School Of Medicine

• UCLA

• Uc San Francisco

Conditions Treated

---

• AdRenal Gland Cancer
• Anal and Rectal Cancer
• Anemia
• Bladder Cancer
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

• Aetna
• Blue Card PPO
• CaliforniaCare HMO
• Select Plus HMO
• Brown & Toland Physicians
• Commercial Insurance Company
• Delta Health System
• Medicare Advantage PFFS
• Kaiser Permanente
• Medicaid
• Medicare MCR
• PacifiCare HMO
• United Healthcare

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• UCSF
• UCLA Medical Center
• Stanford University School of Medicine

Hospital

---

• UCSF Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Siddhartha Mitra, MD This Doctor is OpenDoctor Recommended.
	Dr. Jagan Muppidi, MD This Doctor is OpenDoctor Recommended.
	Dr. Lawrence D. Kaplan, MD This Doctor is OpenDoctor Recommended.
	Dr. Adam S. Giermasz, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Alan B. Newman, MD
	Dr. Christopher C. Benz, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Rahul R. Aggarwal, MD This Doctor is OpenDoctor Recommended.
	Dr. Laurence M. Corash, MD
	Dr. Joan E. Etzell, MD This Doctor is OpenDoctor Recommended.
	Dr. Karin L. Gaensler, MD This Doctor is OpenDoctor Recommended.
	Dr. Andrew C. Hsieh, MD This Doctor is OpenDoctor Recommended.
	Dr. Hugh J. Lawrence, MD This Doctor is OpenDoctor Recommended.
	Dr. Lawrence Fong, MD This Doctor is OpenDoctor Recommended.
	Dr. Gallia G. Levy, MD This Doctor is OpenDoctor Recommended.
	Dr. Wei Wang, MD This Doctor is OpenDoctor Recommended.
	Dr. David H. Kirn, MD
	Dr. Yehoda M. Martei, MD
	Dr. Neil P. Shah, MD
	Xiao X. Wei

---

Doctor Directory | TOS | twitter | FB | Angel | blog